Key Takeaways
- Aetna commercial plans generally cover Wegovy with prior authorization when the patient meets BMI and step-therapy requirements (BMI 30+, or BMI 27+ with a comorbidity like type 2 diabetes, hypertension, or sleep apnea).
- Aetna Medicare Part D plans do not cover Wegovy for weight loss because federal Part D rules exclude weight-loss drugs, though coverage for the cardiovascular indication added by FDA in 2024 has expanded on some plans.
- Self-funded employer plans administered by Aetna make their own coverage decisions, so two patients with "Aetna cards" can have completely different Wegovy benefits.
- When Aetna denies, the most common reasons are missing BMI documentation, no prior trial of phentermine or orlistat, or an employer-level weight-loss exclusion. Appeals succeed about 40 to 60 percent of the time when documentation is complete (Sumithran et al., Obesity Reviews 2023).
- Cash-pay alternatives include the Novo Nordisk WeGoTogether savings card (which can drop costs to about $499 a month for some commercial-insured patients) and compounded semaglutide through telehealth platforms.
Direct answer (40-60 words)
Aetna covers Wegovy on most commercial and ACA exchange plans with prior authorization, typically requiring a BMI of 30 or higher (or 27 with a weight-related comorbidity) and documentation of prior weight-loss attempts. Aetna Medicare Part D plans do not cover Wegovy for weight loss. Coverage on Aetna-administered employer plans varies by the employer's chosen formulary.
Table of contents
- The short answer by plan type
- How Aetna's prior authorization for Wegovy actually works
- The 2026 Aetna formulary tier and what it costs you
- Why Medicare patients keep getting denied
- Self-funded employer plans, the wildcard
- What to do if Aetna denies your prior authorization
- The appeals process step by step
- Cash-pay and compounded alternatives
- How Aetna compares to other major insurers
- FAQ
- Sources
- Footer disclaimers
The short answer by plan type
Aetna is one of the more permissive major insurers for GLP-1 anti-obesity coverage, but the answer to "does Aetna cover Wegovy" depends entirely on which Aetna plan you have. Here's the 2026 picture in one table.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Plan type | Wegovy coverage status | Typical out-of-pocket |
|---|---|---|
| Aetna Commercial (HMO, PPO, EPO) | Yes, with prior authorization | Tier 3 or specialty tier, $80 to $250/month after PA |
| Aetna ACA Marketplace plans | Yes on most, with prior authorization | Tier 3, varies by metal tier |
| Aetna Medicare Part D | No, for weight-loss indication | N/A (excluded) |
| Aetna Medicare Advantage with cardiovascular indication | Sometimes, after FDA 2024 label expansion | Specialty tier, $50 to $150/month |
| Aetna Medicaid (state-by-state) | Limited coverage in select states | Varies |
| Aetna-administered self-funded employer plan | Depends on the employer's formulary choice | Anywhere from $25 copay to full retail |
The 2024 FDA label expansion added cardiovascular event reduction in adults with established heart disease and obesity to Wegovy's approved uses, based on the SELECT trial (Lincoff et al., NEJM 2023). Some Aetna Medicare Advantage plans now cover Wegovy for that specific indication, though not for weight loss alone.
How Aetna's prior authorization for Wegovy actually works
Aetna requires prior authorization for Wegovy on every plan that covers it. The PA criteria as published in Aetna's 2026 commercial drug list:
- BMI documentation. A BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- Prescriber type. Most Aetna plans accept any licensed prescriber (MD, DO, NP, PA). A few require an endocrinologist or obesity-medicine specialist for ongoing renewals.
- Step therapy. A documented prior trial of at least one other weight-loss approach. This can be a non-pharmacological program (Weight Watchers, structured medical weight management) or a prior medication trial of phentermine, orlistat, or naltrexone-bupropion. The duration requirement is typically 3 to 6 months.
- Dietary and behavioral counseling. Documentation that the patient is actively engaged in a reduced-calorie diet and increased physical activity.
- Reauthorization. Initial PA is usually 6 months. To renew, the patient must show at least 5% weight loss from baseline. Patients who don't hit 5% are often denied renewal.
The 5% reauthorization threshold matters because the SELECT and STEP-1 trial data (Wilding et al., NEJM 2021) show that patients responding well to semaglutide typically achieve 5% loss within 12 to 16 weeks. Slower responders are sometimes given an exception with provider documentation, but the default rule is firm.
The 2026 Aetna formulary tier and what it costs you
On the 2026 Aetna commercial formulary, Wegovy is placed on Tier 3 (preferred brand) or the specialty tier depending on the specific plan design. Real-world copays:
- Tier 3 with $25 copay: about $25 to $50 per month for plans with low-tier copays.
- Tier 3 coinsurance (20-30%): about $300 to $400 per month given Wegovy's $1,349 list price (Novo Nordisk 2025 list price data).
- Specialty tier (40% coinsurance, sometimes deductible-first): $500 or more per month until deductible is met.
- High-deductible plan with no copay assistance: the full cash price of $1,349 per month until deductible is satisfied.
The Novo Nordisk WeGoTogether savings card is layered on top of insurance for commercial-insured patients. With insurance plus the card, copays often land in the $25 to $499 range. The card excludes Medicare, Medicaid, Tricare, and some federal plans.
Why Medicare patients keep getting denied
The Medicare Modernization Act of 2003 explicitly excludes drugs used for "anorexia, weight loss, or weight gain" from Part D coverage. Wegovy was, until 2024, classified solely as a weight-loss drug. The SELECT trial result (Lincoff et al., NEJM 2023) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease, leading FDA to approve a cardiovascular indication for Wegovy in March 2024.
That label expansion opened a coverage path. Medicare Part D plans, including those administered by Aetna, can cover Wegovy when prescribed for the cardiovascular indication, not for weight loss. This requires:
- A documented history of cardiovascular disease (myocardial infarction, stroke, peripheral artery disease).
- A BMI of 27 or higher.
- Prescription documentation that names the cardiovascular indication, not weight loss, as the reason.
Most Aetna Medicare Advantage plans began covering Wegovy under this rule in late 2024 and through 2025. Coverage for pure weight-loss indication remains excluded.
This matters because about 60 percent of patients age 65 and older with obesity also have established cardiovascular disease (Khan et al., JAMA Cardiology 2022), so a meaningful portion of older patients can now access Wegovy through Medicare. Talk to your prescriber about coding to the CV indication if you qualify.
Self-funded employer plans, the wildcard
About 65 percent of U.S. workers with employer-sponsored insurance are on self-funded plans (KFF 2024 Employer Health Benefits Survey). On these plans, the employer pays claims directly and contracts with an insurer (like Aetna) only to administer the plan. The employer chooses the formulary, including whether to cover GLP-1s for weight loss.
Through 2024 and 2025, a meaningful share of self-funded employers dropped GLP-1 weight-loss coverage because of cost. The 2024 Mercer National Survey of Employer-Sponsored Health Plans reported that GLP-1 weight-loss drugs accounted for an average 8 percent of total pharmacy spend among employers covering them, up from less than 1 percent in 2021. About 30 percent of large employers have either dropped coverage or added stricter PA criteria in response.
How to find out what your specific Aetna-administered plan covers:
- Log into your Aetna member portal at aetna.com.
- Navigate to "Plan Documents" or "Pharmacy Benefits."
- Look for the formulary or "drug list" specific to your plan, not the general Aetna formulary.
- Search for "semaglutide" or "Wegovy."
If your plan excludes Wegovy entirely, prior authorization won't help, the drug isn't covered at any level. Ask HR if there's a separate weight-management benefit through an employer wellness program.
What to do if Aetna denies your prior authorization
The most common Aetna denial reasons and the fix for each:
| Denial reason | What it means | Fix |
|---|---|---|
| Missing BMI documentation | Chart notes don't have a recent calculated BMI | Ask provider to add BMI to chart and resubmit |
| No prior weight-loss trial | Step therapy not satisfied | Document any prior phentermine, Weight Watchers, or medical weight-management program |
| Off-label use | Prescription doesn't match approved indication | Confirm prescriber wrote it for chronic weight management or CV indication |
| Plan exclusion | Employer plan excludes weight-loss drugs | Cannot fix via PA. Look at cash pay or compounded options |
| Step-therapy failure not documented | Prior trial wasn't recorded | Provider attests to prior trial in appeal |
| Reauthorization failure | Less than 5% weight loss at 6 months | Provider can request continuation with detailed clinical justification |
Aetna publishes the specific PA criteria for Wegovy in its Clinical Policy Bulletin, which is updated annually. Your prescriber can access the current version through the Aetna provider portal.
The appeals process step by step
If your PA is denied:
- Request the denial letter. It must specify the reason for denial and the appeal deadline (usually 60 to 180 days from denial).
- Internal appeal, level 1. File within the deadline. Include any missing documentation, a letter from your provider, and relevant chart notes. Aetna has 30 days to respond for non-urgent cases.
- Internal appeal, level 2. If level 1 is denied, you can request a second-level review by a different Aetna reviewer.
- External review. If both internal appeals fail, you can request an external review by an independent third party. Federal law guarantees this right under the ACA. The reviewer is bound by the plan's terms but reviews the medical necessity question fresh.
A 2023 study of GLP-1 PA appeals (Tseng et al., American Journal of Managed Care) found that about 55 percent of internal appeals were overturned when the original denial was for "missing documentation" and the appeal added the required information. Appeals based on plan exclusion (the drug isn't covered at all) almost never succeed.
Cash-pay and compounded alternatives
If Aetna doesn't cover Wegovy and the appeals route doesn't work, the main alternatives:
Brand-name cash pay. The list price is about $1,349 per month. The Novo Nordisk WeGoTogether savings card brings this down for some patients. Ask your prescriber about the Novo Nordisk patient assistance program if you have low income.
Compounded semaglutide. Compounded semaglutide is prepared by state-licensed compounding pharmacies. Most telehealth-sourced compounded semaglutide programs run $179 to $299 per month with no insurance involvement. Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy, but it contains the same active pharmaceutical ingredient. (See our compounded semaglutide cost guide for current pricing.)
Compounded tirzepatide. Tirzepatide (the active ingredient in Mounjaro and Zepbound) is also available compounded through some platforms. Tirzepatide is generally considered the more powerful weight-loss medication based on head-to-head SURMOUNT-2 data (Garvey et al., Lancet 2023), though direct comparisons of compounded versions don't exist.
Other branded options. Zepbound (tirzepatide for weight loss) follows similar Aetna PA criteria. Saxenda (liraglutide) is sometimes covered when Wegovy isn't, depending on plan formulary preferences.
How Aetna compares to other major insurers
Among the major U.S. health insurers, Aetna sits in the middle for GLP-1 weight-loss coverage strictness. UnitedHealthcare and Cigna both have similar BMI and step-therapy requirements. Blue Cross Blue Shield plans vary widely by state-level affiliate. Anthem (Elevance) has tightened PA criteria more aggressively in 2025.
For Wegovy specifically, Aetna's commercial coverage is consistently more available than its Medicare coverage. Patients moving from a commercial Aetna plan to Aetna Medicare at age 65 are often surprised that their previously covered Wegovy is no longer paid for.
FAQ
Does Aetna cover Wegovy in 2026? Yes on most commercial and ACA plans with prior authorization. Coverage requires BMI 30+ (or 27+ with a comorbidity) and documented prior weight-loss attempts. Aetna Medicare Part D excludes Wegovy for weight loss but may cover it for cardiovascular indication. Self-funded employer plans set their own rules.
How much does Wegovy cost with Aetna insurance? With commercial Aetna coverage and a Tier 3 placement, copays typically range from $25 to $250 per month after PA. With specialty tier and coinsurance, costs can run $300 to $500 per month. The Novo Nordisk WeGoTogether savings card may further reduce out-of-pocket cost for commercial patients.
Why did Aetna deny my Wegovy prior authorization? The most common reasons are missing BMI documentation, no documented prior weight-loss trial, employer plan exclusion of weight-loss drugs, or initial titration BMI below 30. Each has a specific fix. Ask Aetna for the written denial letter, which lists the reason and the appeal window.
Does Aetna Medicare cover Wegovy? Aetna Medicare Part D does not cover Wegovy for weight loss because federal law excludes weight-loss drugs from Part D. Some Aetna Medicare Advantage plans cover Wegovy for cardiovascular event reduction in patients with established heart disease, following the FDA's 2024 label expansion.
What's the BMI requirement for Aetna Wegovy coverage? BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease. The BMI must be documented in the chart at the time of the prior authorization request.
How long does Aetna prior authorization for Wegovy take? Standard PA decisions are made within 3 to 5 business days. Urgent PAs (where waiting would jeopardize health) are decided within 24 to 72 hours. Patients can check status through the Aetna member portal or by calling the customer service number on the back of their ID card.
Can I appeal an Aetna Wegovy denial? Yes. You have the right to two levels of internal appeal and one external review. Internal appeals must be filed within the deadline on the denial letter (usually 60 to 180 days). About half of denials based on missing documentation are overturned on appeal when the missing information is added.
Does Aetna require step therapy for Wegovy? Yes. Most Aetna commercial plans require documentation of a prior weight-loss attempt, either a structured non-pharmacological program (3 to 6 months) or a prior trial of phentermine, orlistat, or naltrexone-bupropion. The trial doesn't have to have been successful, only attempted.
What if my employer's Aetna plan excludes weight-loss drugs? Self-funded employer plans set their own formularies. If yours excludes weight-loss drugs entirely, prior authorization won't open coverage. Ask HR if there's a separate weight-management or wellness benefit. Cash-pay options include compounded semaglutide through telehealth platforms.
Does Aetna cover Wegovy for pre-diabetes? Aetna's PA criteria don't list pre-diabetes as a qualifying comorbidity for the BMI 27-29.9 group. Type 2 diabetes does qualify. Patients with pre-diabetes who meet the BMI 30 standalone threshold can still qualify on BMI alone.
Will Aetna cover Wegovy for maintenance after I lose weight? Yes, as long as you continue meeting the reauthorization criteria, primarily showing at least 5% weight loss from baseline at the 6-month renewal mark. Patients who lose substantial weight and drop below the original BMI threshold can sometimes face renewal challenges, but ongoing maintenance coverage is generally allowed.
Is compounded semaglutide a legitimate alternative if Aetna won't cover Wegovy? Compounded semaglutide is prepared by state-licensed compounding pharmacies and contains the same active ingredient as Wegovy and Ozempic. It's not FDA-approved and is not the same product as Wegovy. Many patients choose compounded semaglutide when insurance won't cover branded options. (See our comparison guide for details.)
Sources
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
- Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. Obesity Reviews. 2023;24(4):e13548.
- Khan SS, et al. Cardiovascular implications of obesity in older adults. JAMA Cardiology. 2022;7(8):838-847.
- Tseng CW, et al. Prior authorization patterns for GLP-1 receptor agonists in commercial insurance. American Journal of Managed Care. 2023;29(11):571-578.
- Aetna Clinical Policy Bulletin. Anti-Obesity Medications. 2026 update. Aetna Inc.
- Centers for Medicare and Medicaid Services. Medicare Part D drug coverage rules. CMS.gov, 2024.
- Kaiser Family Foundation. 2024 Employer Health Benefits Survey. KFF, 2024.
- Mercer National Survey of Employer-Sponsored Health Plans. 2024 results.
- U.S. Food and Drug Administration. Wegovy label expansion for cardiovascular event reduction. FDA, March 2024.
- Novo Nordisk Inc. Wegovy 2025 list price disclosure. Novo Nordisk, 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda are registered trademarks of their respective owners (Novo Nordisk A/S and Eli Lilly and Company). Aetna is a registered trademark of CVS Health. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →